Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VP-102 Cantharidin film forming · 1 trial · 12 indications
Cohort 1: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the EOS Visit (Day 84).
Cohort 2: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the EOT Visit (Day 84).
| Arm | Type | Description |
|---|---|---|
| VP-102 | EXPERIMENTAL | Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator. |
| Name | Type | Description |
|---|---|---|
| VP-102 Cantharidin topical film forming solution | COMBINATION_PRODUCT | VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 14 days between treatments. |
| VP-102 Cantharidin, topical film forming solution | COMBINATION_PRODUCT | VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 21 days between treatments. |
Inclusion Criteria: 1. Be healthy, immunocompetent males or females at least 2 years of age and older for Cohort 1 and 12 years of age and older for Cohort 2. 2. Present with 1-6 common warts (verruca vulgaris) located anywhere on the body except for the following prohibited areas: the eye area (in...
VP-102 Cantharidin film forming is an investigational small molecule being developed for the treatment of common warts, also known as verruca vulgaris. It is a topical film-forming formulation of cantharidin, a substance derived from blister beetles, that is applied directly to the wart. The drug is currently in Phase 2 clinical development.
VP-102 Cantharidin film forming is being developed by Verrica Pharmaceuticals Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VRCA. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for the treatment of common warts.
VP-102 Cantharidin film forming is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The drug is being studied for the treatment of common warts, and a Phase 2 clinical trial has been completed to evaluate its effects.
VP-102 Cantharidin film forming has been studied in one clinical trial with the identifier NCT03487549, titled 'Cantharidin and Occlusion in Verruca Epithelium.' This Phase 2 trial enrolled 56 participants with common warts and was completed in the United States. The trial was uncontrolled and did not use randomization or blinding.
VP-102 Cantharidin film forming is a specific formulation of cantharidin, a chemical compound derived from blister beetles. The drug is designed as a film-forming topical solution that delivers cantharidin to the skin. It is being developed by Verrica Pharmaceuticals for the treatment of common warts.